Search Results - "Szepietowski, J. C."

Psoriasis flare‐up associated with second dose of Pfizer‐BioNTech BNT16B2b2 COVID‐19 mRNA vaccine by Krajewski, P.K., Matusiak, Ł., Szepietowski, J.C.

Get full text

Immune thrombocytopenic purpura associated with COVID‐19 Pfizer‐BioNTech BNT16B2b2 mRNA vaccine by Krajewski, P. K., Szepietowski, J. C.

Get full text

Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients by Matusiak, Ł., Bieniek, A., Szepietowski, J.C.

“…Summary Background The management of hidradenitis suppurativa (HS) is still challenging, and new treatment methods are necessary. Acitretin seems to be a…”
Get full text

European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa by Zouboulis, C.C., Desai, N., Emtestam, L., Hunger, R.E., Ioannides, D., Juhász, I., Lapins, J., Matusiak, L., Prens, E.P., Revuz, J., Schneider-Burrus, S., Szepietowski, J.C., van der Zee, H.H., Jemec, G.B.E.

“…Hidradenitis suppurativa/acne inversa (HS) is a chronic, inflammatory, recurrent, debilitating skin disease of the hair follicle that usually presents after…”
Get full text

Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity by Zouboulis, C.C., Tzellos, T., Kyrgidis, A., Jemec, G.B.E., Bechara, F.G., Giamarellos‐Bourboulis, E.J., Ingram, J.R., Kanni, T., Karagiannidis, I., Martorell, A., Matusiak, Ł., Pinter, A., Prens, E.P., Presser, D., Schneider‐Burrus, S., von Stebut, E., Szepietowski, J.C., Zee, H.H., Wilden, S.M., Sabat, R., Sinclair, R., Vekic, D., Haes, P., Marmol, V., Alavi, A., Gulliver, W., Nassif, A., Nikolakis, G., Podda, M., Antoniou, C., Delli, F.S., Dessinioti, C., Patsatsi, A., Trigoni, A.P., Zisimou, C., Bettoli, V., Garcovich, S., Boer, J., Horváth, B., Ingvarsson, G., Puig, L., Hunger, R.E., Emtestam, L., Danby, F.W., Kimball, A.B.

“…Summary Background A validated tool for the dynamic severity assessment of hidradenitis suppurativa/acne inversa (HS) is lacking. Objectives To develop and…”
Get full text

Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate‐to‐severe chronic plaque psoriasis: a randomized, double‐blind, Fumaderm®‐ and placebo‐controlled trial (BRIDGE) by Mrowietz, U., Szepietowski, J.C., Loewe, R., Kerkhof, P., Lamarca, R., Ocker, W.G., Tebbs, V.M., Pau‐Charles, I.

“…Summary Background Fumaric acid esters (FAEs) are recommended in international guidelines for induction and long‐term treatment of adults with…”
Get full text

Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label OPTIMISE study by Reich, K., Puig, L., Szepietowski, J.C., Paul, C., Lacour, J.P., Tsianakas, A., Sieder, C., Rissler, M., Pournara, E., Orsenigo, R.

“…Summary Background Secukinumab is a fully human monoclonal antibody that selectively binds to and neutralizes interleukin‐17A. Objectives To assess the…”
Get full text

Quality of life assessment in core outcome sets: A position statement of the EADV Task Force on Quality of Life and Patient Oriented Outcomes by Chernyshov, P.V., Evers, A.W.M., Bewley, A., Tomas‐Aragones, L., Marron, S.E., Manolache, L., Pustišek, N., Abeni, D., Sampogna, F., Linder, M.D., Salek, M.S., Szepietowski, J.C.

“…Core outcome sets (COSs) are an agreed standardized collection of outcomes that should be measured and reported in all clinical trials for a specific clinical…”
Get full text

S2k guideline for treatment of cutaneous lupus erythematosus – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV) by Kuhn, A., Aberer, E., Bata‐Csörgő, Z., Caproni, M., Dreher, A., Frances, C., Gläser, R., Klötgen, H.‐W., Landmann, A., Marinovic, B., Nyberg, F., Olteanu, R., Ranki, A., Szepietowski, J.C., Volc‐Platzer, B.

“…Cutaneous lupus erythematosus (CLE) is a rare inflammatory autoimmune disease with heterogeneous clinical manifestations. To date, no therapeutic agents have…”
Get full text

The burden of common skin diseases assessed with the EQ5D™: a European multicentre study in 13 countries by Balieva, F., Kupfer, J., Lien, L., Gieler, U., Finlay, A.Y., Tomás‐Aragonés, L., Poot, F., Misery, L., Sampogna, F., Middendorp, H., Halvorsen, J.A., Szepietowski, J.C., Lvov, A., Marrón, S.E., Salek, M.S., Dalgard, F.J.

“…Summary Background Generic instruments measuring health‐related quality of life (HRQoL), like EQ5D™, enable comparison of skin diseases with healthy…”
Get full text

Quimp (quality of life impairment): an addition to the quality of life lexicon by Chernyshov, P.V., Linder, M.D., Pustišek, N., Manolache, L., Szepietowski, J.C., Tomas‐Aragones, L., Marron, S.E., Poot, F., Augustin, M., Bewley, A., van Cranenburgh, O.D., Jemec, G.B., Salek, M.S., Sampogna, F., Svensson, A.

Get full text

Granulocyte–macrophage colony‐stimulating factor (GM‐CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐GM‐CSF monoclonal antibody by Papp, K.A., Gooderham, M., Jenkins, R., Vender, R., Szepietowski, J.C., Wagner, T., Hunt, B., Souberbielle, B.

“…Summary Background The relevance of granulocyte–macrophage colony‐stimulating factor (GM‐CSF) in the management of psoriasis has not been studied previously…”
Get full text

Self-management-competency as a new target in Hidradenitis suppurativa care by Mann, C, Staubach, P, Grabbe, S, Wegner, J, Hennig, K, Nikolakis, G, Szepietowski, J C, Matusiak, L, von Stebut, E, Kirschner, U, Podda, M, Garcovich, S, Schultheis, M

“…Hidradenitis suppurativa affects approximately 1% of the population. Highlighting the relevance of self-management-competency as a new therapeutic target. 258…”
Get full text

Opioid-induced pruritus: an update by Reich, A., Szepietowski, J. C.

“…Summary Pruritus is an unpleasant sensation leading to scratching. It can be a feature of numerous skin or systemic diseases, and may also be a side‐effect of…”
Get full text

A consensus-based practical and daily guide for the treatment of acne patients by Gollnick, H.P., Bettoli, V., Lambert, J., Araviiskaia, E., Binic, I., Dessinioti, C., Galadari, I., Ganceviciene, R., Ilter, N., Kaegi, M., Kemeny, L., López-Estebaranz, J.L., Massa, A., Oprica, C., Sinclair, W., Szepietowski, J.C., Dréno, B.

“…Background Many current guidelines provide detailed evidence‐based recommendations for acne treatment. Objective To create consensus‐based, simple, easy‐to‐use…”
Get full text

The New Insight into the Role of Antimicrobial Proteins-Alarmins in the Immunopathogenesis of Psoriasis by Szepietowski, J. C., Wolf, R., Maj, J., Batycka-Baran, A.

“…The pathognesis of psoriasis still remains not fully elucidated. Recent advances favor the idea that interactions between innate and adaptive immune response…”
Get full text

Itch: scratching more than the surface by Twycross, R., Greaves, M.W., Handwerker, H., Jones, E.A., Libretto, S.E., Szepietowski, J.C., Zylicz, Z.

“…In origin, itch can be cutaneous (‘pruritoceptive’, e.g. dermatitis), neuropathic (e.g. multiple sclerosis), neurogenic (e.g. cholestasis), mixed (e.g…”
Get full text

Pilonidal sinus disease: an intergluteal localization of hidradenitis suppurativa/acne inversa: a cross‐sectional study among 2465 patients by Benhadou, F., Van der Zee, H.H., Pascual, J.C., Rigopoulos, D., Katoulis, A., Liakou, A.I., Daxhelet, M., Romanelli, M., Iannone, M., Kinyó, Á., Nikolakis, G., Zouboulis, C.C., Dessinioti, C., Zisimou, C., Antoniou, C., Alavi, A., Mintoff, D., Aquilina, S., Matusiak, L., Szepietowski, J.C., Sinclair, R., Husein‐ElAhmed, H., von Laffert, M., Revuz, J., Danby, B., Puig, L., Theut Riis, P., Jemec, G.B.E., van Straalen, K., Wigny, K.M.G.J., Marmol, V., Guillem, P.

“…Summary Background Hidradenitis suppurativa (HS), also referred to as acne inversa, is a debilitating skin disease characterized by inflammatory nodules,…”
Get full text

Secukinumab re‐initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis by Blauvelt, A., Reich, K., Warren, R.B., Szepietowski, J.C., Sigurgeirsson, B., Tyring, S. K., Messina, I., Bhosekar, V., Oliver, J., Papavassilis, C., Frueh, J., Langley, R.G.B.

Get full text

EADV Task Force Pruritus White Paper on chronic pruritus and chronic prurigo: Current challenges and future solutions by Ständer, S, Pereira, M P, Zeidler, C, Legat, F J, Misery, L, Lönndahl, L, Bewley, A P, Brenaut, E, Bobko, S, Elberling, J, Evers, A W M, Garcovich, S, Gieler, U, Gonçalo, M, Kupfer, J, Lambert, J, Lvov, A, Metz, M, Michenko, A, Papadavid, E, Reich, A, Savk, E, Schneider, G, Schut, C, Serra-Baldrich, E, Ständer, H F, Szepietowski, J C, Wallengren, J, Weisshaar, E, Augustin, M

“…Chronic pruritus (CP) is frequent in general medicine and the most common complaint in general dermatology. The prevalence of CP is expected to rise in the…”
Get full text